Non-Small Cell Lung Cancer: Dual-Modality PET/CT in Preoperative Staging

Radiology

Volumn 229, Issue 2, 2003, Pages 526-533

  Antoch, Gerald ^a   Stattaus, Jörg ^a   Nemat, Andre T ^b   Marnitz, Simone ^a   Beyer, Thomas ^a   Kuehl, Hilmar ^a   Bockisch, Andreas ^a   Debatin, Jörg F ^a   Freudenberg, Lutz S ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Ruhrlandclinic ^*  (Germany)

Author keywords

Lung neoplasms; Lung neoplasms, CT; Lung neoplasms, PET; Lung neoplasms, staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SURGERY; LYMPH NODE METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0142240448     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2292021598     Document Type: Article

References (29)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
2. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002; 122:1037-1057.
3. AJCC cancer staging manual. 6th ed. New York, NY: Springer, 2002; 165-177.
4. Smythe WR. Treatment of stage I and II non-small cell lung cancer. Cancer Control 2001; 8:318-325.
5. Haura EB. Treatment of advanced non-small cell lung cancer: a review of current randomised clinical trials and an examination of emerging therapies. Cancer Control 2001; 8:326-336.
6. Barker JM, Silvestri GA. Lung cancer staging. Curr Opin Pulm Med 2002; 8:287-293.
7. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (< 1 cm), intermediate (1 to 3 cm), and large (> 3 cm) lymph node lesions. Chest 2000; 117:773-778.
8. Marom EM, McAdams PH, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212:803-809.
9. Pieterman RM, van Putten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343:254-261.
10. Gupta NC, Graeber GM, Rogers JS, Bishop HA. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann Surg 1999; 229:286-291.
11. Weber WA, Avril N, Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 1999; 175:356-373.
12. Townsend DW. A combined PET-CT scanner: the choices. J Nucl Med 2001; 42:533-534.
13. Beyer T, Townsend DW, Brun T, et al. A combined PET-CT scanner for clinical oncology. J Nucl Med 2000; 41:1369-1379.
14. Beyer T, Townsend DW, Blodgett TM. Dual-modality PET-CT tomography for clinical oncology. Q J Nucl Med 2002; 46:24-34.
15. von Schulthess GK. Cost considerations regarding an integrated CT-PET system. Eur Radiol 2000; 10:S377-S380.
16. Kinahan PE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a combined 3D PET-CT scanner. Med Phys 1998; 25:2046-2053.
17. Hawkins RA, Choi Y, Huang SC, et al. Quantitating tumor glucose metabolism with FDG and PET. J Nucl Med 1992; 33:339-344.
18. Huang SC. Anatomy of SUV. Nucl Med Biol 2000; 27:643-646.
19. Antoch G, Egelhof T, Korfee S, Frings M, Forsting M, Bockisch A. Recurrent schwannoma: diagnosis with PET-CT. Neurology 2002; 59:1240.
20. Glazer GM, Gross BH, Quint LE, et al. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. AJR Am J Roentgenol 1985; 144:261-265.
21. Lowe VJ, DeLong DM, Hoffmann JM, et al. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 1995; 36:883-887.
22. Deslauriers J, Gregoire J. Clinical and surgical staging of non-small cell lung cancer. Chest 2000; 117:96S-103S.
23. Stapels CA, Muller NL, Miller RR, et al. Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy. Radiology 1988; 167:367-372.
24. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl R. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999; 213:530-536.
25. Haag DW, Follette DM, Roberts PF, Shelton D, Segel LD, Taylor TM. Advantages of positron emission tomography over computed tomography in mediastinal staging of non-small cell lung cancer. J Surg Res 2002; 103:160-164.
26. Lee JD, Ginsberg RJ. Lung cancer staging: the value of ipsilateral scalene lymph node biopsy performed at mediastinoscopy. Ann Thorac Surg 1996; 62:338-341.
27. Weder W, Schmid RA, Bruchhaus H, Hillinger S, von Schulthess GK, Steinert HC. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998; 66:886-893.
28. Antoch G, Freudenberg LS, Stattaus J, et al. Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol 2002; 179:1555-1560.
29. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions. JAMA 2001; 285:914-924.